Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: maeda t. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M. Hotta K, et al. Among authors: maeda t. J Thorac Oncol. 2010 Feb;5(2):179-84. doi: 10.1097/JTO.0b013e3181ca12e0. J Thorac Oncol. 2010. PMID: 20101144 Free article.
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K. Aoe K, et al. Among authors: maeda t. Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26. Eur J Cancer. 2014. PMID: 25172295 Clinical Trial.
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K. Kubo T, et al. Among authors: maeda t. Cancer Chemother Pharmacol. 2016 Oct;78(4):769-74. doi: 10.1007/s00280-016-3135-2. Epub 2016 Aug 20. Cancer Chemother Pharmacol. 2016. PMID: 27544764 Clinical Trial.
Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.
Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T, Matsuo K, Kato K, Kanehiro A, Tanimoto Y, Matsuo K, Ueoka H, Tanimoto M. Hotta K, et al. Among authors: maeda t. Cancer J. 2005 Sep-Oct;11(5):417-24. doi: 10.1097/00130404-200509000-00010. Cancer J. 2005. PMID: 16259873
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, Yoshioka H, Hayashi H, Kawai H, Aoe K, Maeda T, Ueoka H, Tanimoto M. Segawa Y, et al. Among authors: maeda t. J Thorac Oncol. 2010 Sep;5(9):1430-4. doi: 10.1097/JTO.0b013e3181e3248e. J Thorac Oncol. 2010. PMID: 20651615 Free article. Clinical Trial.
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Horinouchi H, et al. Among authors: maeda t. Cancer Med. 2020 Sep;9(18):6597-6608. doi: 10.1002/cam4.3306. Epub 2020 Jul 30. Cancer Med. 2020. PMID: 32730697 Free PMC article.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
5,653 results